{"protocolSection":{"identificationModule":{"nctId":"NCT00556712","orgStudyIdInfo":{"id":"BO18192"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy"},"statusModule":{"statusVerifiedDate":"2015-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-01"},"primaryCompletionDateStruct":{"date":"2010-11","type":"ACTUAL"},"completionDateStruct":{"date":"2010-11","type":"ACTUAL"},"studyFirstSubmitDate":"2007-11-09","studyFirstSubmitQcDate":"2007-11-09","studyFirstPostDateStruct":{"date":"2007-11-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-04","resultsFirstSubmitQcDate":"2015-01-27","resultsFirstPostDateStruct":{"date":"2015-02-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-27","lastUpdatePostDateStruct":{"date":"2015-02-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease progression or unacceptable toxicity during chemotherapy. Following 4 cycles of platinum-based chemotherapy, eligible patients will be randomized to receive either Tarceva 150mg po daily, or placebo daily. The anticipated time on study treatment is until disease progression; the target sample size is 500+ individuals."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":889,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Erlotinib","type":"EXPERIMENTAL","description":"Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.","interventionNames":["Drug: erlotinib [Tarceva]"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150mg po daily","armGroupLabels":["Erlotinib"]},{"type":"DRUG","name":"Placebo","description":"po daily","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)","description":"Progression-free survival (PFS) was defined as the time from randomization to PD or death, whichever occurred first. For target lesions (TLs), PD was defined at least a 20 percent (%) increase in the sum of the largest diameter (SLD), taking as reference the smallest SLD recorded from baseline (BL) more the appearance of one or more new lesions. For non-target lesions (NTLs), PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","timeFrame":"Screening, BL [≤21 days after randomization], every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"PFS in All Participants (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from BL more the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Percentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤ 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Percentage of All Participants Who Died (Data Cutoff 12 January 2012)","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)."},{"measure":"Overall Survival (OS) in All Participants (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤ 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)"},{"measure":"Probable Percentage of Participants Remaining Alive at 1 Year (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"1 year"},{"measure":"Percentage of EGFR IHC Positive Participants Who Died (Data Cutoff 12 January 2012)","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)"},{"measure":"OS in EGFR IHC Positive Population (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)"},{"measure":"Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive at 1 Year (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"1 year"},{"measure":"Percentage of EGFR IHC Negative Participants With PD or Death (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 71 months)"},{"measure":"PFS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Percentage of EGFR IHC Negative Participants Who Died (Data Cutoff 17 May 2008)","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"OS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive at 1 Year (Data Cutoff 17 May 2008)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"1 year"},{"measure":"Time to Progression (Data Cutoff 17 May 2008)","description":"The median time, in weeks, between randomization and TTP event. Participants without PD were censored at the date of last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of PD, the participant was censored at the date of last tumor assessment before starting new chemotherapy.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants Remaining Progression-Free in the TTP Analysis at 6 Months (Data Cutoff 17 May 2008)","description":"TTP was defined as the time from the date of randomization to the first date PD was recorded. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD were censored at the date of last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of PD, the participant was censored at the date of last tumor assessment before starting new chemotherapy. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008)","description":"BOR was defined as CR or PR confirmed by repeat assessments performed no less than 4 weeks after the criteria for response was first met. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Percentage of Participants With a CR, PR, Stable Disease (SD), or PD According to RECIST (Data Cutoff 17 May 2008)","description":"For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Percentage of Participants With a Response Upgrade From BL According to RECIST (Data Cutoff 17 May 2008)","description":"Response upgrade was defined by a change of PR to CR or of SD to PR or CR from BL to the end of treatment. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008)","description":"For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008)","description":"Disease control was defined as a best response of CR or PR or SD or a best response of SD for more than 12 weeks, or CR or PR. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Percentage of Participants With Symptom Progression Assessed Using the Lung Cancer Subscale (LCS) (Data Cutoff 17 May 2008)","description":"LCS scores were obtained from a 7-item questionnaire from the Functional Assessment of Cancer Therapy - Lung (FACT-L) version (V) 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 equaled (=) \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Time to Symptom Progression (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization to the date of documented clinically meaningful decline in LCS from BL or death, whichever occurred first. LCS scores were obtained from a 7-item questionnaire from the FACT-L V 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline. The 95% CI was determined using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants Remaining Without Symptom Progression at 6 Months (Data Cutoff 17 May 2008)","description":"LCS scores were obtained from a 7-item questionnaire from the FACT-L V 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Percentage of Participants With Deterioration Assessed Using the Trial Outcome Index (Data Cutoff 17 May 2008)","description":"The Trial Outcome Index (TOI) was defined as the sum of the scores of the Physical Well-Being (PWB), Functional Well-Being (FWB), and LCS. PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Time to Deterioration in TOI (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization until a clinically meaningful decline from BL in TOI or death, whichever occurred first. TOI was defined as the sum of PWB, FWB, and LCS scores, which were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was determined using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants Remaining Without Deterioration in TOI at 6 Months (Data Cutoff 17 May 2008)","description":"TOI was defined as the sum of the scores of the PWB, FWB, and LCS. PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Percentage of Participants With Deterioration in Quality of Life Assessed Using TOI, SWB, and EWB (Data Cutoff 17 May 2008)","description":"Deterioration in quality of life (QoL) was defined as a clinically meaningful decline in the total FACT-L score, the sum of the TOI, Social/Family Well-Being (SWB) and Emotional Well-Being (EWB) of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Time to Deterioration in QoL (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization until a clinically meaningful decline from BL in total FACT-L or death, whichever occurred first. Total FACT-L score was defined as the sum of the TOI, SWB and EWB of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was determined using Kaplan-Meier methodology.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Probable Percentage of Participants Remaining Without Deterioration in QoL at 6 Months (Data Cutoff 17 May 2008)","description":"Deterioration in QoL was defined as a clinically meaningful decline in the total FACT-L score, the sum of the TOI, SWB and EWB of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L. The 95% CI was estimated using Kaplan-Meier methodology.","timeFrame":"6 months"},{"measure":"Functional Assessment of Chronic Illness Therapy - Lung (FACT-L) Scores (Data Cutoff 17 May 2008)","description":"Total FACT-L score=sum of TOI, SWB, and EWB of FACT-L questionnaires. TOI (PWB+FWB+LCS), SWB, and EWB scores obtained from 7-item (6-item for EWB) questionnaires from FACT-L V4. Participants responded to questions assessing symptoms (scale 0-4; 0=\"not at all\" and 4=\"very much\"). Higher score=more severe symptoms. The 7-item LCS assessed symptoms such as shortness of breath, loss of weight, tightness in chest. Participants responded to questions assessing symptoms (scale: 0-4; 0=\"not at all\" and 4=\"very much\"). Scores from 0-35; higher score=more severe symptoms. The 27 items of FACT-G were scored in the following domains: PWB (7 items, total score 0-28), SWB (7 items; total score 0-28), EWB (6 items, total score 0-24), and FWB (7 items; total score 0-28), higher scores=better QoL. Participants responded to items on 5-point Likert scale (0=\"Not at all\" to 4=\"Very much\"; total score: 0-108). Higher score=better QOL. TOI score=PWB+FWB+LCS; Total TOI score: 0-92; higher scores=better QOL.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"},{"measure":"Change From BL in FACT-L Scores (Data Cutoff 17 May 2008)","description":"Total FACT-L score=sum of TOI, SWB, and EWB of FACT-L questionnaires. TOI (PWB+FWB+LCS), SWB, and EWB scores obtained from 7-item (6-item for EWB) questionnaires from FACT-L V4. Participants responded to questions assessing symptoms (scale 0-4; 0=\"not at all\" and 4=\"very much\"). Higher score=more severe symptoms. The 7-item LCS assessed symptoms such as shortness of breath, loss of weight, tightness in chest. Participants responded to questions assessing symptoms (scale: 0-4; 0=\"not at all\" and 4=\"very much\"). Scores from 0-35; higher score=more severe symptoms. The 27 items of FACT-G were scored in the following domains: PWB (7 items, total score 0-28), SWB (7 items; total score 0-28), EWB (6 items, total score 0-24), and FWB (7 items; total score 0-28), higher scores=better QoL. Participants responded to items on 5-point Likert scale (0=\"Not at all\" to 4=\"Very much\"; total score: 0-108). Higher score=better QOL. TOI score=PWB+FWB+LCS; Total TOI score: 0-92; higher scores=better QOL.","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients \\>=18 years of age;\n* histologically documented, locally advanced , recurrent or metastatic NSCLC;\n* measurable disease;\n* no disease progression after 4 cycles of platinum-based chemotherapy.\n\nExclusion Criteria:\n\n* unstable systemic disease;\n* any other malignancies in the last 5 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"city":"Waratah","state":"New South Wales","zip":"2298","country":"Australia","geoPoint":{"lat":-32.90667,"lon":151.72647}},{"city":"Brisbane","state":"Queensland","zip":"4101","country":"Australia","geoPoint":{"lat":-27.46794,"lon":153.02809}},{"city":"Adelaide","state":"South Australia","zip":"5041","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"city":"East Bentleigh","state":"Victoria","zip":"VIC 3165","country":"Australia"},{"city":"Fitzroy","state":"Victoria","zip":"3065","country":"Australia","geoPoint":{"lat":-37.79839,"lon":144.97833}},{"city":"Geelong","state":"Victoria","zip":"3220","country":"Australia","geoPoint":{"lat":-38.14711,"lon":144.36069}},{"city":"Melbourne","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"city":"Innsbruck","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"city":"Klagenfurt","zip":"9010","country":"Austria","geoPoint":{"lat":46.62472,"lon":14.30528}},{"city":"Vienna","zip":"1140","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"city":"Vienna","zip":"1145","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"city":"Antwerp","zip":"2020","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"city":"Winnipeg","state":"Manitoba","zip":"R3E 0V9","country":"Canada","geoPoint":{"lat":49.8844,"lon":-97.14704}},{"city":"Oshawa","state":"Ontario","zip":"L1G 2B9","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"city":"Sault Ste. Marie","state":"Ontario","zip":"P6A 2C4","country":"Canada","geoPoint":{"lat":46.51677,"lon":-84.33325}},{"city":"Toronto","state":"Ontario","zip":"M4C 3E7","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"city":"Laval","state":"Quebec","zip":"H7M 3L9","country":"Canada","geoPoint":{"lat":45.56995,"lon":-73.692}},{"city":"Montreal","state":"Quebec","zip":"H4J 1C5","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"city":"Santiago","zip":"0000","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"city":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"city":"Guangzhou","zip":"510060","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"České Budějovice","zip":"370 87","country":"Czechia","geoPoint":{"lat":48.97447,"lon":14.47434}},{"city":"Olomouc","zip":"775 20","country":"Czechia","geoPoint":{"lat":49.59552,"lon":17.25175}},{"city":"Pilsen","zip":"305 99","country":"Czechia","geoPoint":{"lat":49.74747,"lon":13.37759}},{"city":"Herlev","zip":"2730","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"city":"Bayonne","zip":"64100","country":"France","geoPoint":{"lat":43.49316,"lon":-1.473}},{"city":"Brest","zip":"29200","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"city":"Clermont-Ferrand","zip":"63003","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"city":"Le Mans","zip":"72037","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"city":"Lille","zip":"59020","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"city":"Paris","zip":"75674","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75908","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Pau","zip":"64046","country":"France","geoPoint":{"lat":43.31117,"lon":-0.35583}},{"city":"Toulouse","zip":"31400","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"city":"Vandœuvre-lès-Nancy","zip":"54511","country":"France","geoPoint":{"lat":48.66115,"lon":6.17114}},{"city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"city":"Bochum","zip":"44791","country":"Germany","geoPoint":{"lat":51.48165,"lon":7.21648}},{"city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"city":"Herne","zip":"44625","country":"Germany","geoPoint":{"lat":51.5388,"lon":7.22572}},{"city":"Neuruppin","zip":"16816","country":"Germany","geoPoint":{"lat":52.92815,"lon":12.80311}},{"city":"Villingen-Schwenningen","zip":"78052","country":"Germany","geoPoint":{"lat":48.06226,"lon":8.49358}},{"city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"city":"Athens","zip":"14564","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"city":"Heraklion","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"city":"Budapest","zip":"1122","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"city":"Budapest","zip":"1529","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"city":"Pécs","zip":"7635","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"city":"Szombathely","zip":"9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"city":"Bologna","state":"Emilia-Romagna","zip":"40139","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"city":"Rome","state":"Lazio","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Ancona","state":"The Marches","country":"Italy","geoPoint":{"lat":43.60717,"lon":13.5103}},{"city":"Kaunas","country":"Lithuania","geoPoint":{"lat":54.90156,"lon":23.90909}},{"city":"Klaipėda","zip":"92288","country":"Lithuania","geoPoint":{"lat":55.7068,"lon":21.13912}},{"city":"Vilnius","zip":"08660","country":"Lithuania","geoPoint":{"lat":54.68916,"lon":25.2798}},{"city":"George Town","zip":"11200","country":"Malaysia","geoPoint":{"lat":5.41123,"lon":100.33543}},{"city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"city":"Amsterdam","zip":"1081 HV","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"city":"Flushing","zip":"4382 EE","country":"Netherlands","geoPoint":{"lat":51.4425,"lon":3.57361}},{"city":"Heerlen","zip":"6419 PC","country":"Netherlands","geoPoint":{"lat":50.88365,"lon":5.98154}},{"city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"city":"Auckland","zip":"1009","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"city":"Lodz","zip":"91-520","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"city":"Lodz","zip":"94-306","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"city":"Cluj-Napoca","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"city":"Iași","zip":"6600","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"city":"Timișoara","zip":"1900","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"city":"Balashikha","zip":"143900","country":"Russia","geoPoint":{"lat":55.79479,"lon":37.94794}},{"city":"Chelyabinsk","zip":"454 087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"city":"Kazan'","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"city":"Kazan'","zip":"420111","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"city":"Kirov","country":"Russia","geoPoint":{"lat":58.59809,"lon":49.65783}},{"city":"Krasnodar","zip":"350040","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"city":"Krasnodar","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"city":"Kuzmolovo","zip":"188663","country":"Russia"},{"city":"Moscow","zip":"105203","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"117837","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"125284","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Nizhny Novgorod","zip":"603000","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"city":"Perm","zip":"614 066","country":"Russia","geoPoint":{"lat":58.01046,"lon":56.25017}},{"city":"Saint Petersburg","zip":"191015","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","zip":"195067","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Sashi","zip":"354057","country":"Russia","geoPoint":{"lat":58.46061,"lon":49.80111}},{"city":"Smolensk","country":"Russia","geoPoint":{"lat":54.77826,"lon":32.05088}},{"city":"Yaroslavl","zip":"150054","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"city":"Banská Bystrica","zip":"975 17","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"city":"Bratislava","zip":"825 56","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"city":"Nitra","zip":"949 88","country":"Slovakia","geoPoint":{"lat":48.30763,"lon":18.08453}},{"city":"Poprad","zip":"058 87","country":"Slovakia","geoPoint":{"lat":49.06144,"lon":20.29798}},{"city":"Golnik","country":"Slovenia","geoPoint":{"lat":46.33333,"lon":14.33333}},{"city":"Ljubljana","zip":"1000","country":"Slovenia","geoPoint":{"lat":46.05108,"lon":14.50513}},{"city":"Maribor","country":"Slovenia","geoPoint":{"lat":46.55583,"lon":15.64593}},{"city":"Durban","zip":"4091","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"city":"Johannesburg","zip":"2196","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"city":"Pretoria","zip":"0001","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"city":"Daegu","zip":"700-712","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"city":"Seoul","zip":"110-744","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"120-752","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"139-709","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Suwon","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"city":"Santander","state":"Cantabria","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"city":"A Coruña","state":"La Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"city":"Oviedo","state":"Principality of Asturias","zip":"33006","country":"Spain","geoPoint":{"lat":43.36029,"lon":-5.84476}},{"city":"Valencia","state":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"city":"Zaragoza","state":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"city":"Kharkiv","zip":"61024","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"city":"Zaporizhzhya","zip":"69104","country":"Ukraine","geoPoint":{"lat":47.85167,"lon":35.11714}},{"city":"Chelmsford","zip":"CM1 7ET","country":"United Kingdom","geoPoint":{"lat":51.73575,"lon":0.46958}},{"city":"Dundee","zip":"DD1 9SY","country":"United Kingdom","geoPoint":{"lat":56.46913,"lon":-2.97489}},{"city":"Leicester","zip":"LE1 5WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"city":"Plymouth","zip":"PL6 8DH","country":"United Kingdom","geoPoint":{"lat":50.37153,"lon":-4.14305}},{"city":"Caracas","zip":"1062","country":"Venezuela","geoPoint":{"lat":10.48801,"lon":-66.87919}}]},"referencesModule":{"references":[{"pmid":"20493771","type":"DERIVED","citation":"Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) were randomized to receive a placebo, orally (PO) as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"FG001","title":"Erlotinib, 150 Milligrams Per Day (mg/Day)","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"451"},{"groupId":"FG001","numSubjects":"438"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Data cutoff date: 17 May 2008","numSubjects":"0"},{"groupId":"FG001","comment":"Data cutoff date: 17 May 2008","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"451"},{"groupId":"FG001","numSubjects":"438"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"320"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Refused Treatment","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Failure to Return","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Ongoing at Data Cutoff","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"66"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS): all randomized participants presented according to the therapy that they were randomized to receive","groups":[{"id":"BG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"BG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"451"},{"groupId":"BG001","value":"438"},{"groupId":"BG002","value":"889"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.7","spread":"9.39"},{"groupId":"BG001","value":"59.8","spread":"9.52"},{"groupId":"BG002","value":"59.8","spread":"9.44"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"230"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"338"},{"groupId":"BG001","value":"321"},{"groupId":"BG002","value":"659"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)","description":"Progression-free survival (PFS) was defined as the time from randomization to PD or death, whichever occurred first. For target lesions (TLs), PD was defined at least a 20 percent (%) increase in the sum of the largest diameter (SLD), taking as reference the smallest SLD recorded from baseline (BL) more the appearance of one or more new lesions. For non-target lesions (NTLs), PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","populationDescription":"FAS; participants with PD prior to randomization were excluded from analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL [≤21 days after randomization], every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"437"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5"},{"groupId":"OG001","value":"79.9"}]}]}]},{"type":"PRIMARY","title":"PFS in All Participants (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; participants with PD prior to randomization were excluded from analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"437"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"8.1","upperLimit":"11.7"},{"groupId":"OG001","value":"12.3","lowerLimit":"12.0","upperLimit":"13.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"0.82"}]},{"type":"PRIMARY","title":"Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from BL more the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; participants with PD prior to randomization were excluded from analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"437"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"12.0","upperLimit":"19.0"},{"groupId":"OG001","value":"25.0","lowerLimit":"21.0","upperLimit":"29.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","populationDescription":"FAS; only participants with EGFR IHC positive tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"307"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4"},{"groupId":"OG001","value":"79.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of All Participants Who Died (Data Cutoff 12 January 2012)","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months).","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"438"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1"},{"groupId":"OG001","value":"82.0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) in All Participants (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Screening, BL (≤ 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"438"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.9","upperLimit":"12.0"},{"groupId":"OG001","value":"12.4","lowerLimit":"10.6","upperLimit":"13.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0097","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"0.96"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants Remaining Alive at 1 Year (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 year","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"438"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","lowerLimit":"41.0","upperLimit":"50.0"},{"groupId":"OG001","value":"50.0","lowerLimit":"45.0","upperLimit":"55.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of EGFR IHC Positive Participants Who Died (Data Cutoff 12 January 2012)","populationDescription":"FAS; only participants with EGFR IHC positive tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"308"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5"},{"groupId":"OG001","value":"80.5"}]}]}]},{"type":"SECONDARY","title":"OS in EGFR IHC Positive Population (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC positive tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 12 January 2012 (up to 71 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"308"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.7","upperLimit":"12.8"},{"groupId":"OG001","value":"12.8","lowerLimit":"11.1","upperLimit":"14.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0050","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"0.93"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive at 1 Year (Data Cutoff 12 January 2012)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 year","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"308"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","lowerLimit":"41.0","upperLimit":"52.0"},{"groupId":"OG001","value":"52.0","lowerLimit":"47.0","upperLimit":"58.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of EGFR IHC Negative Participants With PD or Death (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented.","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 71 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8"},{"groupId":"OG001","value":"77.4"}]}]}]},{"type":"SECONDARY","title":"PFS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"6.4","upperLimit":"12.0"},{"groupId":"OG001","value":"11.0","lowerLimit":"6.6","upperLimit":"13.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1768","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"1.14"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"2.0","upperLimit":"20.0"},{"groupId":"OG001","value":"22.0","lowerLimit":"11.0","upperLimit":"34.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of EGFR IHC Negative Participants Who Died (Data Cutoff 17 May 2008)","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8"},{"groupId":"OG001","value":"41.9"}]}]}]},{"type":"SECONDARY","title":"OS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"7.4","upperLimit":"11.2"},{"groupId":"OG001","value":"8.6","lowerLimit":"7.4","upperLimit":"NA","comment":"The upper limit of the 95% CI could not be calculated due to the large number of censored events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4797","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"1.40"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive at 1 Year (Data Cutoff 17 May 2008)","description":"OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Patients who have not died at the time of the final analysis will be censored at the date the patient was last known to be alive. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC negative tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 year","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"3.0","upperLimit":"37.0"},{"groupId":"OG001","value":"42.0","lowerLimit":"25.0","upperLimit":"59.0"}]}]}]},{"type":"SECONDARY","title":"Time to Progression (Data Cutoff 17 May 2008)","description":"The median time, in weeks, between randomization and TTP event. Participants without PD were censored at the date of last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of PD, the participant was censored at the date of last tumor assessment before starting new chemotherapy.","populationDescription":"FAS; participants with PD prior to randomization were excluded from analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"437"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"8.1","upperLimit":"11.9"},{"groupId":"OG001","value":"12.3","lowerLimit":"12.0","upperLimit":"14.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.61","ciUpperLimit":"0.82"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants Remaining Progression-Free in the TTP Analysis at 6 Months (Data Cutoff 17 May 2008)","description":"TTP was defined as the time from the date of randomization to the first date PD was recorded. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD were censored at the date of last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of PD, the participant was censored at the date of last tumor assessment before starting new chemotherapy. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; participants with PD prior to randomization were excluded from analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"437"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"11.0","upperLimit":"19.0"},{"groupId":"OG001","value":"26.0","lowerLimit":"21.0","upperLimit":"30.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008)","description":"BOR was defined as CR or PR confirmed by repeat assessments performed no less than 4 weeks after the criteria for response was first met. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","populationDescription":"FAS; only participants with CR, PR or SD at BL as determined by the Investigator were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"436"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"3.5","upperLimit":"7.9"},{"groupId":"OG001","value":"11.9","lowerLimit":"9.0","upperLimit":"15.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"Chi-squared","paramType":"Difference in Response Rates","paramValue":"6.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.7","ciUpperLimit":"10.3","estimateComment":"The approximate 95% CI for the difference of two rates was determined using the Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With a CR, PR, Stable Disease (SD), or PD According to RECIST (Data Cutoff 17 May 2008)","description":"For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","populationDescription":"FAS; only participants with CR, PR or SD at BL as determined by the Investigator were included in the analysis; and 7 and 17 participants were not assessed from the Placebo and Erlotinib, 150 mg/day groups, respectively.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"436"}]}],"classes":[{"title":"CR","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.1","upperLimit":"2.0"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.3","upperLimit":"2.3"}]}]},{"title":"PR","categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"2.9","upperLimit":"7.1"},{"groupId":"OG001","value":"11.0","lowerLimit":"8.2","upperLimit":"14.3"}]}]},{"title":"SD","categories":[{"measurements":[{"groupId":"OG000","value":"45.4","lowerLimit":"40.7","upperLimit":"50.1"},{"groupId":"OG001","value":"48.6","lowerLimit":"43.8","upperLimit":"53.4"}]}]},{"title":"PD","categories":[{"measurements":[{"groupId":"OG000","value":"47.6","lowerLimit":"42.9","upperLimit":"52.4"},{"groupId":"OG001","value":"35.6","lowerLimit":"31.1","upperLimit":"40.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response Upgrade From BL According to RECIST (Data Cutoff 17 May 2008)","description":"Response upgrade was defined by a change of PR to CR or of SD to PR or CR from BL to the end of treatment. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","populationDescription":"FAS; only participants with CR, PR or SD at BL as determined by the Investigator were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"436"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.5","upperLimit":"2.9"},{"groupId":"OG001","value":"5.5","lowerLimit":"3.6","upperLimit":"8.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0007","statisticalMethod":"Chi-squared","paramType":"Difference in Response Upgrade Rates","paramValue":"4.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.6","ciUpperLimit":"6.7","estimateComment":"The approximate 95% CI for the difference of two rates was determined using the Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008)","description":"For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","populationDescription":"FAS; only participants with CR, PR or SD at BL as determined by the Investigator were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"436"}]}],"classes":[{"title":"PR to CR","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.6"}]}]},{"title":"SD to PR","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.3"},{"groupId":"OG001","value":"4.8","lowerLimit":"3.0","upperLimit":"7.3"}]}]},{"title":"SD to CR","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"1.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008)","description":"Disease control was defined as a best response of CR or PR or SD or a best response of SD for more than 12 weeks, or CR or PR. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD/incomplete response was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits. The 95% CI for one sample binomial was determined using the Pearson-Clopper method.","populationDescription":"FAS; only participants with CR, PR or SD at BL as determined by the Investigator were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"445"},{"groupId":"OG001","value":"436"}]}],"classes":[{"title":"CR Plus (+) PR + SD","categories":[{"measurements":[{"groupId":"OG000","value":"50.8","lowerLimit":"46.0","upperLimit":"55.5"},{"groupId":"OG001","value":"60.6","lowerLimit":"55.8","upperLimit":"65.2"}]}]},{"title":"CR + PR + SD >12 Weeks","categories":[{"measurements":[{"groupId":"OG000","value":"27.4","lowerLimit":"23.3","upperLimit":"31.8"},{"groupId":"OG001","value":"40.8","lowerLimit":"36.2","upperLimit":"45.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis included CR + PR + SD rate.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0035","statisticalMethod":"Chi-squared","paramType":"Difference in Disease Control Rates","paramValue":"9.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.1","ciUpperLimit":"16.4","estimateComment":"Approximate 95% CI for the difference of two rates was determined using the Hauck-Anderson method."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis included CR + PR + SD \\> 12 weeks rate.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Chi-squared","paramType":"Difference in Disease Control Rates","paramValue":"13.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.1","ciUpperLimit":"19.7","estimateComment":"Approximate 95% CI for the difference of two rates was determined using the Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptom Progression Assessed Using the Lung Cancer Subscale (LCS) (Data Cutoff 17 May 2008)","description":"LCS scores were obtained from a 7-item questionnaire from the Functional Assessment of Cancer Therapy - Lung (FACT-L) version (V) 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 equaled (=) \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline.","populationDescription":"FAS; 56 and 48 participants were not evaluated for this outcome measure from the Placebo and Erlotinib groups, respectively.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"395"},{"groupId":"OG001","value":"390"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1"},{"groupId":"OG001","value":"47.7"}]}]}]},{"type":"SECONDARY","title":"Time to Symptom Progression (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization to the date of documented clinically meaningful decline in LCS from BL or death, whichever occurred first. LCS scores were obtained from a 7-item questionnaire from the FACT-L V 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline. The 95% CI was determined using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"395"},{"groupId":"OG001","value":"390"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","lowerLimit":"12.4","upperLimit":"19.1"},{"groupId":"OG001","value":"18.3","lowerLimit":"13.1","upperLimit":"24.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3787","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.12"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants Remaining Without Symptom Progression at 6 Months (Data Cutoff 17 May 2008)","description":"LCS scores were obtained from a 7-item questionnaire from the FACT-L V 4. Participants responded to questions assessing symptoms commonly reported by lung cancer patients; such as shortness of breath, loss of weight, and tightness in chest; on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" The participants' responses were summed to result in an overall score, where a higher score indicated more severe symptoms. A change of 2 to 3 points in score was determined to be a clinically meaningful decline. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"395"},{"groupId":"OG001","value":"390"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"27.0","upperLimit":"42.0"},{"groupId":"OG001","value":"41.0","lowerLimit":"34.0","upperLimit":"47.0"}]}]}]},{"type":"PRIMARY","title":"PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from randomization to PFS event. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS;only participants with EGFR IHC positive tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤ 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"307"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"7.1","upperLimit":"11.7"},{"groupId":"OG001","value":"12.3","lowerLimit":"12.0","upperLimit":"17.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"< 0.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.58","ciUpperLimit":"0.82"}]},{"type":"PRIMARY","title":"Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008)","description":"PFS was defined as the time from randomization to PD or death, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without PD or death were censored at the date of last tumor assessment where non-progression was documented. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS; only participants with EGFR IHC positive tumors were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"307"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"12.0","upperLimit":"21.0"},{"groupId":"OG001","value":"27.0","lowerLimit":"22.0","upperLimit":"32.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Deterioration Assessed Using the Trial Outcome Index (Data Cutoff 17 May 2008)","description":"The Trial Outcome Index (TOI) was defined as the sum of the scores of the Physical Well-Being (PWB), Functional Well-Being (FWB), and LCS. PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment.","populationDescription":"FAS; 59 and 49 participants were not evaluated for this outcome measure from the Placebo and Erlotinib groups, respectively.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"389"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1"},{"groupId":"OG001","value":"50.9"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration in TOI (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization until a clinically meaningful decline from BL in TOI or death, whichever occurred first. TOI was defined as the sum of PWB, FWB, and LCS scores, which were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was determined using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"389"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","lowerLimit":"13.6","upperLimit":"24.1"},{"groupId":"OG001","value":"18.1","lowerLimit":"12.3","upperLimit":"19.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5385","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"1.31"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants Remaining Without Deterioration in TOI at 6 Months (Data Cutoff 17 May 2008)","description":"TOI was defined as the sum of the scores of the PWB, FWB, and LCS. PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"389"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","lowerLimit":"34.0","upperLimit":"48.0"},{"groupId":"OG001","value":"39.0","lowerLimit":"33.0","upperLimit":"45.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Deterioration in Quality of Life Assessed Using TOI, SWB, and EWB (Data Cutoff 17 May 2008)","description":"Deterioration in quality of life (QoL) was defined as a clinically meaningful decline in the total FACT-L score, the sum of the TOI, Social/Family Well-Being (SWB) and Emotional Well-Being (EWB) of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L.","populationDescription":"FAS; 62 and 51 participants were not evaluated for this outcome measure from the Placebo and Erlotinib groups, respectively,","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"387"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7"},{"groupId":"OG001","value":"55.3"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration in QoL (Data Cutoff 17 May 2008)","description":"The median time, in weeks, from the date of randomization until a clinically meaningful decline from BL in total FACT-L or death, whichever occurred first. Total FACT-L score was defined as the sum of the TOI, SWB and EWB of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L assessment. The 95% CI was determined using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"387"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","lowerLimit":"11.9","upperLimit":"17.9"},{"groupId":"OG001","value":"12.6","lowerLimit":"12.1","upperLimit":"18.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6530","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.16"}]},{"type":"SECONDARY","title":"Probable Percentage of Participants Remaining Without Deterioration in QoL at 6 Months (Data Cutoff 17 May 2008)","description":"Deterioration in QoL was defined as a clinically meaningful decline in the total FACT-L score, the sum of the TOI, SWB and EWB of the FACT-L questionnaires. TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L V 4. Participants responded to questions assessing symptoms on a scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Higher score indicated more severe symptoms. A clinically meaningful decline in FACT-L score was defined as at least a 6 point decline from BL. Participants without a clinically meaningful decline in TOI at the time of analysis were censored at the time of the last FACT-L. The 95% CI was estimated using Kaplan-Meier methodology.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"387"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","lowerLimit":"27.0","upperLimit":"40.0"},{"groupId":"OG001","value":"32.0","lowerLimit":"26.0","upperLimit":"38.0"}]}]}]},{"type":"SECONDARY","title":"Functional Assessment of Chronic Illness Therapy - Lung (FACT-L) Scores (Data Cutoff 17 May 2008)","description":"Total FACT-L score=sum of TOI, SWB, and EWB of FACT-L questionnaires. TOI (PWB+FWB+LCS), SWB, and EWB scores obtained from 7-item (6-item for EWB) questionnaires from FACT-L V4. Participants responded to questions assessing symptoms (scale 0-4; 0=\"not at all\" and 4=\"very much\"). Higher score=more severe symptoms. The 7-item LCS assessed symptoms such as shortness of breath, loss of weight, tightness in chest. Participants responded to questions assessing symptoms (scale: 0-4; 0=\"not at all\" and 4=\"very much\"). Scores from 0-35; higher score=more severe symptoms. The 27 items of FACT-G were scored in the following domains: PWB (7 items, total score 0-28), SWB (7 items; total score 0-28), EWB (6 items, total score 0-24), and FWB (7 items; total score 0-28), higher scores=better QoL. Participants responded to items on 5-point Likert scale (0=\"Not at all\" to 4=\"Very much\"; total score: 0-108). Higher score=better QOL. TOI score=PWB+FWB+LCS; Total TOI score: 0-92; higher scores=better QOL.","populationDescription":"FAS; n=number of participants assessed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"392"}]}],"classes":[{"title":"BL: Physical Well-Being (n=397,392)","categories":[{"measurements":[{"groupId":"OG000","value":"20.85","spread":"4.817"},{"groupId":"OG001","value":"20.96","spread":"4.781"}]}]},{"title":"BL: Social Well-Being (n=397,392)","categories":[{"measurements":[{"groupId":"OG000","value":"20.84","spread":"5.496"},{"groupId":"OG001","value":"20.98","spread":"5.285"}]}]},{"title":"BL: Emotional Well-Being (n=397,393)","categories":[{"measurements":[{"groupId":"OG000","value":"16.92","spread":"4.534"},{"groupId":"OG001","value":"16.77","spread":"4.862"}]}]},{"title":"BL: Functional Well-Being (n=397,393)","categories":[{"measurements":[{"groupId":"OG000","value":"16.15","spread":"5.488"},{"groupId":"OG001","value":"16.84","spread":"5.514"}]}]},{"title":"BL: FACT-L Subscale Score (n=397,391)","categories":[{"measurements":[{"groupId":"OG000","value":"24.17","spread":"4.892"},{"groupId":"OG001","value":"24.46","spread":"4.697"}]}]},{"title":"BL: Lung Cancer Subscale Score (n=397,391)","categories":[{"measurements":[{"groupId":"OG000","value":"19.82","spread":"4.188"},{"groupId":"OG001","value":"20.07","spread":"4.240"}]}]},{"title":"BL: Total FACT-General (FACT-G) Score (n=396,391)","categories":[{"measurements":[{"groupId":"OG000","value":"74.68","spread":"14.787"},{"groupId":"OG001","value":"75.52","spread":"14.612"}]}]},{"title":"BL: Trial Outcome Index (n=396,390)","categories":[{"measurements":[{"groupId":"OG000","value":"56.83","spread":"11.830"},{"groupId":"OG001","value":"57.90","spread":"11.682"}]}]},{"title":"BL: Total FACT-L Score (n=395,389)","categories":[{"measurements":[{"groupId":"OG000","value":"98.85","spread":"18.007"},{"groupId":"OG001","value":"100.02","spread":"17.751"}]}]},{"title":"Week 6: Physical Well-Being (n=274,304)","categories":[{"measurements":[{"groupId":"OG000","value":"21.44","spread":"5.117"},{"groupId":"OG001","value":"20.69","spread":"5.180"}]}]},{"title":"Week 6: Social Well-Being (n=274,303","categories":[{"measurements":[{"groupId":"OG000","value":"20.62","spread":"5.437"},{"groupId":"OG001","value":"21.43","spread":"5.178"}]}]},{"title":"Week 6: Emotional Well-Being (n=275,302)","categories":[{"measurements":[{"groupId":"OG000","value":"16.53","spread":"4.587"},{"groupId":"OG001","value":"17.17","spread":"4.748"}]}]},{"title":"Week 6: Functional Well-Being (n=275,302)","categories":[{"measurements":[{"groupId":"OG000","value":"16.41","spread":"5.234"},{"groupId":"OG001","value":"16.87","spread":"5.614"}]}]},{"title":"Week 6: FACT-L Subscale Score (n=275,300)","categories":[{"measurements":[{"groupId":"OG000","value":"24.45","spread":"5.231"},{"groupId":"OG001","value":"24.80","spread":"5.000"}]}]},{"title":"Week 6: Lung Cancer Subscale Score (n=275,300)","categories":[{"measurements":[{"groupId":"OG000","value":"19.78","spread":"4.463"},{"groupId":"OG001","value":"20.13","spread":"4.336"}]}]},{"title":"Week 6: Total FACT-G Score (n=274,300)","categories":[{"measurements":[{"groupId":"OG000","value":"74.82","spread":"14.380"},{"groupId":"OG001","value":"76.14","spread":"15.132"}]}]},{"title":"Week 6: Trial Outcome Index (n=274,299)","categories":[{"measurements":[{"groupId":"OG000","value":"57.59","spread":"12.292"},{"groupId":"OG001","value":"57.64","spread":"12.482"}]}]},{"title":"Week 6: Total FACT-L Score (n=274,297)","categories":[{"measurements":[{"groupId":"OG000","value":"99.27","spread":"17.857"},{"groupId":"OG001","value":"100.95","spread":"18.360"}]}]},{"title":"Week 12: Physical Well-Being (n=144,194)","categories":[{"measurements":[{"groupId":"OG000","value":"21.93","spread":"4.734"},{"groupId":"OG001","value":"20.78","spread":"5.368"}]}]},{"title":"Week 12: Social Well-Being (n=143,194)","categories":[{"measurements":[{"groupId":"OG000","value":"20.38","spread":"5.637"},{"groupId":"OG001","value":"20.04","spread":"5.691"}]}]},{"title":"Week 12: Emotional Well-Being (n=144,194)","categories":[{"measurements":[{"groupId":"OG000","value":"17.21","spread":"4.376"},{"groupId":"OG001","value":"16.85","spread":"4.521"}]}]},{"title":"Week 12: Functional Well-Being (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"17.04","spread":"5.770"},{"groupId":"OG001","value":"16.35","spread":"5.745"}]}]},{"title":"Week 12: FACT-L Subscale Score (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"25.15","spread":"4.735"},{"groupId":"OG001","value":"24.19","spread":"5.323"}]}]},{"title":"Week 12: Lung Cancer Subscale Score (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"20.22","spread":"4.015"},{"groupId":"OG001","value":"19.50","spread":"4.600"}]}]},{"title":"Week 12: Total FACT-G Score (n=144,192)","categories":[{"measurements":[{"groupId":"OG000","value":"76.42","spread":"14.889"},{"groupId":"OG001","value":"74.06","spread":"15.754"}]}]},{"title":"Week 12: Trial Outcome Index (n=144,194)","categories":[{"measurements":[{"groupId":"OG000","value":"59.19","spread":"12.129"},{"groupId":"OG001","value":"56.57","spread":"13.276"}]}]},{"title":"Week 12: Total FACT-L Score (n=144,192)","categories":[{"measurements":[{"groupId":"OG000","value":"101.56","spread":"17.824"},{"groupId":"OG001","value":"98.30","spread":"19.337"}]}]},{"title":"Week 18: Physical Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"21.60","spread":"4.883"},{"groupId":"OG001","value":"21.40","spread":"4.945"}]}]},{"title":"Week 18: Social Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"21.08","spread":"5.328"},{"groupId":"OG001","value":"19.94","spread":"6.130"}]}]},{"title":"Week 18: Emotional Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"17.33","spread":"4.717"},{"groupId":"OG001","value":"17.14","spread":"4.356"}]}]},{"title":"Week 18: Functional Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"16.89","spread":"5.289"},{"groupId":"OG001","value":"16.83","spread":"5.553"}]}]},{"title":"Week 18: FACT-L Subscale Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"25.44","spread":"4.645"},{"groupId":"OG001","value":"24.52","spread":"5.344"}]}]},{"title":"Week 18: Lung Cancer Subscale Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"20.28","spread":"4.003"},{"groupId":"OG001","value":"19.64","spread":"4.635"}]}]},{"title":"Week 18: Total FACT-G Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"76.89","spread":"14.385"},{"groupId":"OG001","value":"75.31","spread":"16.648"}]}]},{"title":"Week 18: Trial Outcome Index (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"58.76","spread":"11.492"},{"groupId":"OG001","value":"57.87","spread":"12.803"}]}]},{"title":"Week 18: Total FACT-L Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"102.33","spread":"17.502"},{"groupId":"OG001","value":"99.83","spread":"20.558"}]}]},{"title":"Week 24: Physical Well-Being (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"21.78","spread":"4.665"},{"groupId":"OG001","value":"21.21","spread":"4.898"}]}]},{"title":"Week 24: Social Well-Being (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"20.79","spread":"5.641"},{"groupId":"OG001","value":"20.49","spread":"5.251"}]}]},{"title":"Week 24: Emotional Well-Being (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"16.86","spread":"4.880"},{"groupId":"OG001","value":"16.54","spread":"4.615"}]}]},{"title":"Week 24: Functional Well-Being (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"17.14","spread":"6.062"},{"groupId":"OG001","value":"17.23","spread":"5.300"}]}]},{"title":"Week 24: FACT-L Subscale Score (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"25.18","spread":"5.126"},{"groupId":"OG001","value":"25.13","spread":"5.245"}]}]},{"title":"Week 24: Lung Cancer Subscale Score (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"20.07","spread":"4.246"},{"groupId":"OG001","value":"19.94","spread":"4.487"}]}]},{"title":"Week 24: Total FACT-G Score (n=59,99)","categories":[{"measurements":[{"groupId":"OG000","value":"76.58","spread":"16.091"},{"groupId":"OG001","value":"75.50","spread":"15.754"}]}]},{"title":"Week 24: Trial Outcome Index (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"58.99","spread":"11.837"},{"groupId":"OG001","value":"58.37","spread":"12.686"}]}]},{"title":"Week 24: Total FACT-L Score (n=59,99)","categories":[{"measurements":[{"groupId":"OG000","value":"101.75","spread":"19.347"},{"groupId":"OG001","value":"100.69","spread":"19.831"}]}]},{"title":"Week 30: Physical Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"21.74","spread":"4.153"},{"groupId":"OG001","value":"21.77","spread":"4.576"}]}]},{"title":"Week 30: Social Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"20.50","spread":"5.180"},{"groupId":"OG001","value":"20.74","spread":"5.491"}]}]},{"title":"Week 30: Emotional Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"16.37","spread":"4.164"},{"groupId":"OG001","value":"17.23","spread":"4.675"}]}]},{"title":"Week 30: Functional Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"17.92","spread":"5.082"},{"groupId":"OG001","value":"17.93","spread":"5.510"}]}]},{"title":"Week 30: FACT-L Subscale Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"25.90","spread":"3.484"},{"groupId":"OG001","value":"25.86","spread":"4.817"}]}]},{"title":"Week 30: Lung Cancer Subscale Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"20.66","spread":"3.073"},{"groupId":"OG001","value":"20.61","spread":"4.393"}]}]},{"title":"Week 30: Total FACT-G Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"76.54","spread":"11.915"},{"groupId":"OG001","value":"77.66","spread":"15.078"}]}]},{"title":"Week 30: Trial Outcome Index (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"60.32","spread":"9.753"},{"groupId":"OG001","value":"60.30","spread":"11.876"}]}]},{"title":"Week 30: Total FACT-L Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"102.44","spread":"14.063"},{"groupId":"OG001","value":"103.52","spread":"18.367"}]}]},{"title":"Week 36: Physical Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"21.60","spread":"3.317"},{"groupId":"OG001","value":"22.26","spread":"4.480"}]}]},{"title":"Week 36: Social Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"20.02","spread":"5.769"},{"groupId":"OG001","value":"20.15","spread":"4.988"}]}]},{"title":"Week 36: Emotional Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"17.31","spread":"3.736"},{"groupId":"OG001","value":"17.54","spread":"4.540"}]}]},{"title":"Week 36: Fuctional Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"16.06","spread":"4.287"},{"groupId":"OG001","value":"18.06","spread":"5.720"}]}]},{"title":"Week 36: FACT-L Subscale Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"24.48","spread":"4.089"},{"groupId":"OG001","value":"25.83","spread":"5.305"}]}]},{"title":"Week 36: Lung Cancer Subscale Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"19.36","spread":"3.893"},{"groupId":"OG001","value":"20.55","spread":"4.463"}]}]},{"title":"Week 36: Total FACT-G Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"74.99","spread":"11.066"},{"groupId":"OG001","value":"78.02","spread":"15.688"}]}]},{"title":"Week 36: Trial Outcome Index (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"57.02","spread":"9.426"},{"groupId":"OG001","value":"60.87","spread":"11.963"}]}]},{"title":"Week 36: Total FACT-L Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"99.27","spread":"13.672"},{"groupId":"OG001","value":"103.86","spread":"19.244"}]}]},{"title":"Week 42: Physical Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"21.76","spread":"3.592"},{"groupId":"OG001","value":"22.19","spread":"5.035"}]}]},{"title":"Week 42: Social Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"18.45","spread":"6.262"},{"groupId":"OG001","value":"20.40","spread":"5.234"}]}]},{"title":"Week 42: Emotional Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"16.95","spread":"4.089"},{"groupId":"OG001","value":"17.43","spread":"4.984"}]}]},{"title":"Week 42: Functional Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"15.32","spread":"3.902"},{"groupId":"OG001","value":"18.57","spread":"5.500"}]}]},{"title":"Week 42: FACT-L Subscale Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"24.63","spread":"4.448"},{"groupId":"OG001","value":"26.67","spread":"5.357"}]}]},{"title":"Week 42: Lung Cancer Subscale Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"19.50","spread":"4.092"},{"groupId":"OG001","value":"21.21","spread":"4.607"}]}]},{"title":"Week 42: FACT-G Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"72.74","spread":"12.406"},{"groupId":"OG001","value":"78.59","spread":"16.316"}]}]},{"title":"Week 42: Trial Outcome Index (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"56.58","spread":"9.562"},{"groupId":"OG001","value":"61.97","spread":"12.622"}]}]},{"title":"Week 42: FACT-L Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"97.11","spread":"14.951"},{"groupId":"OG001","value":"105.25","spread":"20.385"}]}]},{"title":"Week 48: Physical Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"21.38","spread":"4.154"},{"groupId":"OG001","value":"23.23","spread":"4.016"}]}]},{"title":"Week 48: Social Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"17.23","spread":"7.567"},{"groupId":"OG001","value":"20.24","spread":"5.569"}]}]},{"title":"Week 48: Emotional Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"18.69","spread":"3.011"},{"groupId":"OG001","value":"17.59","spread":"4.903"}]}]},{"title":"Week 48: Functional Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"14.15","spread":"2.672"},{"groupId":"OG001","value":"18.48","spread":"4.501"}]}]},{"title":"Week 48: FACT-L Subscale Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"23.35","spread":"3.647"},{"groupId":"OG001","value":"26.80","spread":"5.591"}]}]},{"title":"Week 48: Lung Cancer Subscale Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"18.75","spread":"3.646"},{"groupId":"OG001","value":"21.21","spread":"4.967"}]}]},{"title":"Week 48: FACT-G Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"71.46","spread":"12.069"},{"groupId":"OG001","value":"79.53","spread":"14.672"}]}]},{"title":"Week 48: Trial Outcome Index (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"54.58","spread":"9.140"},{"groupId":"OG001","value":"62.92","spread":"11.105"}]}]},{"title":"Week 48: FACT-L Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"96.19","spread":"14.394"},{"groupId":"OG001","value":"106.33","spread":"18.701"}]}]},{"title":"Week 60: Physical Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"22.67","spread":"4.664"},{"groupId":"OG001","value":"23.65","spread":"4.212"}]}]},{"title":"Week 60: Social Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"17.78","spread":"6.405"},{"groupId":"OG001","value":"21.31","spread":"6.530"}]}]},{"title":"Week 60: Emotional Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"16.78","spread":"3.232"},{"groupId":"OG001","value":"19.12","spread":"3.638"}]}]},{"title":"Week 60: Functional Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"15.11","spread":"3.408"},{"groupId":"OG001","value":"18.65","spread":"6.828"}]}]},{"title":"Week 60: FACT-L Subscale Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"23.43","spread":"5.010"},{"groupId":"OG001","value":"25.99","spread":"6.844"}]}]},{"title":"Week 60: Lung Cancer Subscale Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"17.89","spread":"3.919"},{"groupId":"OG001","value":"20.47","spread":"5.959"}]}]},{"title":"Week 60: Total FACT-G Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"72.34","spread":"11.607"},{"groupId":"OG001","value":"82.73","spread":"17.803"}]}]},{"title":"Week 60: Trial Outcome Index (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"55.67","spread":"9.695"},{"groupId":"OG001","value":"62.76","spread":"14.316"}]}]},{"title":"Week 60: Total FACT-L Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"95.77","spread":"15.703"},{"groupId":"OG001","value":"108.71","spread":"23.069"}]}]},{"title":"Week 72: Physical Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"22.17","spread":"4.997"},{"groupId":"OG001","value":"23.25","spread":"4.097"}]}]},{"title":"Week 72: Social Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"19.00","spread":"7.251"},{"groupId":"OG001","value":"21.44","spread":"5.852"}]}]},{"title":"Week 72: Emotional Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"17.17","spread":"2.401"},{"groupId":"OG001","value":"18.25","spread":"5.007"}]}]},{"title":"Week 72: Functional Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"15.22","spread":"4.457"},{"groupId":"OG001","value":"16.50","spread":"5.855"}]}]},{"title":"Week 72: FACT-L Subscale Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"21.23","spread":"5.154"},{"groupId":"OG001","value":"26.48","spread":"6.185"}]}]},{"title":"Week 72: Lung Cancer Subscale Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"17.17","spread":"4.021"},{"groupId":"OG001","value":"21.40","spread":"5.724"}]}]},{"title":"Week 72: Total FACT-G Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"73.67","spread":"14.820"},{"groupId":"OG001","value":"79.44","spread":"16.176"}]}]},{"title":"Week 72: Trial Outcome Index (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"54.67","spread":"11.911"},{"groupId":"OG001","value":"61.15","spread":"14.343"}]}]},{"title":"Week 72: Total FACT-L Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"94.90","spread":"18.833"},{"groupId":"OG001","value":"105.92","spread":"21.282"}]}]},{"title":"Week 84: Physical Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"NA","comment":"Standard deviation (SD) not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Social Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"14.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Emotional Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"13.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Functional Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"18.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: FACT-L Subscale Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"17.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Lung Cancer Subscale Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"13.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Total FACT-G Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"65.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Trial Outcome Index (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"51.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Week 84: Total FACT-L Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"82.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants analyzed"}]}]},{"title":"Off Trtmt: Physical Well-Being (n=265,215)","categories":[{"measurements":[{"groupId":"OG000","value":"19.57","spread":"5.668"},{"groupId":"OG001","value":"18.50","spread":"5.534"}]}]},{"title":"Off Trtmt: Social Well-Being (n=263,216)","categories":[{"measurements":[{"groupId":"OG000","value":"20.01","spread":"5.380"},{"groupId":"OG001","value":"20.68","spread":"5.265"}]}]},{"title":"Off Trtmt: Emotional Well-Being (n=265,216)","categories":[{"measurements":[{"groupId":"OG000","value":"14.76","spread":"5.157"},{"groupId":"OG001","value":"15.11","spread":"5.183"}]}]},{"title":"Off Trtmt: Functional Well-Being (n=265,216)","categories":[{"measurements":[{"groupId":"OG000","value":"14.90","spread":"5.893"},{"groupId":"OG001","value":"14.58","spread":"5.934"}]}]},{"title":"Off Trtmt: FACT-L Subscale Score (n=264,214)","categories":[{"measurements":[{"groupId":"OG000","value":"22.80","spread":"5.268"},{"groupId":"OG001","value":"22.88","spread":"4.911"}]}]},{"title":"Off Trtmt: Lung Cancer Subscale Score (n=264,214)","categories":[{"measurements":[{"groupId":"OG000","value":"18.06","spread":"4.629"},{"groupId":"OG001","value":"18.16","spread":"4.383"}]}]},{"title":"Off Trtmt:Total FACT-G Score (n=261,214)","categories":[{"measurements":[{"groupId":"OG000","value":"69.29","spread":"15.730"},{"groupId":"OG001","value":"68.94","spread":"15.669"}]}]},{"title":"Off Trtmt:Trial Outcome Index (n=263,213)","categories":[{"measurements":[{"groupId":"OG000","value":"52.61","spread":"13.475"},{"groupId":"OG001","value":"51.34","spread":"12.974"}]}]},{"title":"Off Trtmt:Total FACT-L Score (n=260,212)","categories":[{"measurements":[{"groupId":"OG000","value":"92.14","spread":"19.324"},{"groupId":"OG001","value":"91.89","spread":"18.738"}]}]}]},{"type":"SECONDARY","title":"Change From BL in FACT-L Scores (Data Cutoff 17 May 2008)","description":"Total FACT-L score=sum of TOI, SWB, and EWB of FACT-L questionnaires. TOI (PWB+FWB+LCS), SWB, and EWB scores obtained from 7-item (6-item for EWB) questionnaires from FACT-L V4. Participants responded to questions assessing symptoms (scale 0-4; 0=\"not at all\" and 4=\"very much\"). Higher score=more severe symptoms. The 7-item LCS assessed symptoms such as shortness of breath, loss of weight, tightness in chest. Participants responded to questions assessing symptoms (scale: 0-4; 0=\"not at all\" and 4=\"very much\"). Scores from 0-35; higher score=more severe symptoms. The 27 items of FACT-G were scored in the following domains: PWB (7 items, total score 0-28), SWB (7 items; total score 0-28), EWB (6 items, total score 0-24), and FWB (7 items; total score 0-28), higher scores=better QoL. Participants responded to items on 5-point Likert scale (0=\"Not at all\" to 4=\"Very much\"; total score: 0-108). Higher score=better QOL. TOI score=PWB+FWB+LCS; Total TOI score: 0-92; higher scores=better QOL.","populationDescription":"FAS; n=number of participants assessed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","groups":[{"id":"OG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."},{"id":"OG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"303"}]}],"classes":[{"title":"Week 6: Physical Well-Being (n=274,303)","categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"4.235"},{"groupId":"OG001","value":"-0.47","spread":"4.729"}]}]},{"title":"Week 6: Social Well-Being (n=274,303)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"4.901"},{"groupId":"OG001","value":"0.23","spread":"4.202"}]}]},{"title":"Week 6: Emotional Well-Being (n=274,302)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"3.801"},{"groupId":"OG001","value":"0.29","spread":"3.916"}]}]},{"title":"Week 6: Functional Well-Being (n=275,302)","categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"4.819"},{"groupId":"OG001","value":"-0.09","spread":"4.711"}]}]},{"title":"Week 6: FACT-L Subscale Score (n=275,298)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"4.899"},{"groupId":"OG001","value":"0.24","spread":"4.623"}]}]},{"title":"Week 6: Lung Cancer Subscale Score (n=275,298)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"4.148"},{"groupId":"OG001","value":"-0.03","spread":"4.160"}]}]},{"title":"Week 6: Total FACT-G Score (n=273,299)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"12.256"},{"groupId":"OG001","value":"0.01","spread":"11.453"}]}]},{"title":"Week 6: Trial Outcome Index (n=274,296)","categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"10.276"},{"groupId":"OG001","value":"-0.73","spread":"10.201"}]}]},{"title":"Week 6: Total FACT-L Score (n=273,294)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"15.133"},{"groupId":"OG001","value":"0.14","spread":"14.155"}]}]},{"title":"Week 12: Physical Well-Being (n=144,193)","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"4.036"},{"groupId":"OG001","value":"-0.14","spread":"4.908"}]}]},{"title":"Week 12: Social Well-Being (n=143,194)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"4.918"},{"groupId":"OG001","value":"-0.43","spread":"5.566"}]}]},{"title":"Week 12: Emotional Well-Being (n=144,194)","categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"3.728"},{"groupId":"OG001","value":"0.20","spread":"4.115"}]}]},{"title":"Week 12: Functional Well-Being (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"4.707"},{"groupId":"OG001","value":"-0.38","spread":"4.806"}]}]},{"title":"Week 12: FACT-L Subscale Score (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"4.501"},{"groupId":"OG001","value":"-0.06","spread":"4.570"}]}]},{"title":"Week 12: Lung Cancer Subscale Score (n=144,196)","categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"3.666"},{"groupId":"OG001","value":"-0.48","spread":"4.004"}]}]},{"title":"Week 12: Total FACT-G Score (n=144,191)","categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"11.637"},{"groupId":"OG001","value":"-0.84","spread":"12.145"}]}]},{"title":"Week 12: Trial Outcome Index (n=144,193)","categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"9.362"},{"groupId":"OG001","value":"-1.04","spread":"10.051"}]}]},{"title":"Week 12: Total FACT-L Score (n=144,191)","categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"14.226"},{"groupId":"OG001","value":"-0.90","spread":"14.536"}]}]},{"title":"Week 18: Physical Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"4.798"},{"groupId":"OG001","value":"0.40","spread":"4.890"}]}]},{"title":"Week 18: Social Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"4.454"},{"groupId":"OG001","value":"-0.51","spread":"5.894"}]}]},{"title":"Week 18: Emotional Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"3.984"},{"groupId":"OG001","value":"0.60","spread":"3.723"}]}]},{"title":"Week 18: Functional Well-Being (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"4.353"},{"groupId":"OG001","value":"0.18","spread":"4.903"}]}]},{"title":"Week 18: FACT-L Subscale Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"4.171"},{"groupId":"OG001","value":"0.27","spread":"4.587"}]}]},{"title":"Week 18: Lung Cancer Subscale Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"3.550"},{"groupId":"OG001","value":"-0.26","spread":"4.125"}]}]},{"title":"Week 18: Total FACT-G Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"12.047"},{"groupId":"OG001","value":"0.68","spread":"12.668"}]}]},{"title":"Week 18: Trial Outcome Index (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":"9.638"},{"groupId":"OG001","value":"0.32","spread":"10.350"}]}]},{"title":"Week 18: Total FACT-L Score (n=86,143)","categories":[{"measurements":[{"groupId":"OG000","value":"4.43","spread":"14.523"},{"groupId":"OG001","value":"0.95","spread":"15.386"}]}]},{"title":"Week 24: Physical Well-Being (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"4.358"},{"groupId":"OG001","value":"0.16","spread":"4.881"}]}]},{"title":"Week 24: Social Well-Being (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"4.804"},{"groupId":"OG001","value":"0.04","spread":"6.092"}]}]},{"title":"Week 24: Emotional Well-Being (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"5.118"},{"groupId":"OG001","value":"-0.05","spread":"4.169"}]}]},{"title":"Week 24: Functional Well-Being (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"4.550"},{"groupId":"OG001","value":"0.42","spread":"4.373"}]}]},{"title":"Week 24: FACT-L Subscale Score (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"5.018"},{"groupId":"OG001","value":"0.50","spread":"5.048"}]}]},{"title":"Week 24: Lung Cancer Subscale Score (n=59,101)","categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"4.051"},{"groupId":"OG001","value":"-0.12","spread":"4.321"}]}]},{"title":"Week 24: Total FACT-G Score (n=59,99)","categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"13.739"},{"groupId":"OG001","value":"0.52","spread":"12.753"}]}]},{"title":"Week 24: Trial Outcome Index (n=59,100)","categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"9.606"},{"groupId":"OG001","value":"0.43","spread":"10.348"}]}]},{"title":"Week 24: Total FACT-L Score (n=59,99)","categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":"16.354"},{"groupId":"OG001","value":"1.10","spread":"15.954"}]}]},{"title":"Week 30: Physical Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"4.205"},{"groupId":"OG001","value":"0.49","spread":"5.129"}]}]},{"title":"Week 30: Social Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"5.510"},{"groupId":"OG001","value":"-0.19","spread":"6.676"}]}]},{"title":"Week 30: Emotional Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"4.902"},{"groupId":"OG001","value":"0.74","spread":"4.775"}]}]},{"title":"Week 30: Functional Well-Being (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"5.028"},{"groupId":"OG001","value":"0.83","spread":"5.243"}]}]},{"title":"Week 30: FACT-L Subscale Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"1.79","spread":"4.616"},{"groupId":"OG001","value":"0.99","spread":"4.863"}]}]},{"title":"Week 30: Lung Cancer Subscale Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"3.818"},{"groupId":"OG001","value":"0.38","spread":"4.454"}]}]},{"title":"Week 30: Total FACT-G Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":"13.827"},{"groupId":"OG001","value":"1.88","spread":"14.268"}]}]},{"title":"Week 30: Trial Outcome Index (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"4.47","spread":"9.551"},{"groupId":"OG001","value":"1.70","spread":"11.108"}]}]},{"title":"Week 30: Total FACT-L Score (n=37,66)","categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":"15.828"},{"groupId":"OG001","value":"2.86","spread":"16.864"}]}]},{"title":"Week 36: Physical Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"4.791"},{"groupId":"OG001","value":"0.77","spread":"5.093"}]}]},{"title":"Week 36: Social Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"5.659"},{"groupId":"OG001","value":"-0.16","spread":"7.053"}]}]},{"title":"Week 36: Emotional Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"4.892"},{"groupId":"OG001","value":"0.65","spread":"3.717"}]}]},{"title":"Week 36: Functional Well-Being (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"5.551"},{"groupId":"OG001","value":"1.10","spread":"5.280"}]}]},{"title":"Week 36: FACT-L Subscale Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"4.864"},{"groupId":"OG001","value":"0.43","spread":"5.459"}]}]},{"title":"Week 36: Lung Cancer Subscale Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"3.963"},{"groupId":"OG001","value":"-0.06","spread":"4.535"}]}]},{"title":"Week 36: Total FACT-G Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"4.02","spread":"14.439"},{"groupId":"OG001","value":"2.37","spread":"13.991"}]}]},{"title":"Week 36: Trial Outcome Index (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"11.186"},{"groupId":"OG001","value":"1.82","spread":"10.443"}]}]},{"title":"Week 36: Total Fact-L Score (n=25,47)","categories":[{"measurements":[{"groupId":"OG000","value":"4.68","spread":"17.636"},{"groupId":"OG001","value":"2.79","spread":"16.662"}]}]},{"title":"Week 42: Physical Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"3.936"},{"groupId":"OG001","value":"0.27","spread":"5.835"}]}]},{"title":"Week 42: Social Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"6.006"},{"groupId":"OG001","value":"0.28","spread":"7.784"}]}]},{"title":"Week 42: Emotional Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"3.573"},{"groupId":"OG001","value":"0.59","spread":"3.741"}]}]},{"title":"Week 42: Functional Well-Being (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"3.582"},{"groupId":"OG001","value":"0.65","spread":"5.580"}]}]},{"title":"Week 42: FACT-L Subscale Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"4.321"},{"groupId":"OG001","value":"0.87","spread":"4.974"}]}]},{"title":"Week 42: Lung Cancer Subscale Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"2.858"},{"groupId":"OG001","value":"0.51","spread":"4.301"}]}]},{"title":"Week 42: FACT-G Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"10.871"},{"groupId":"OG001","value":"1.80","spread":"15.245"}]}]},{"title":"Week 42: Trial Outcome Index (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"7.037"},{"groupId":"OG001","value":"1.44","spread":"12.405"}]}]},{"title":"Week 42: FACT-L Score (n=19,35)","categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"12.466"},{"groupId":"OG001","value":"2.67","spread":"18.499"}]}]},{"title":"Week 48: Physical Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"3.497"},{"groupId":"OG001","value":"1.37","spread":"6.388"}]}]},{"title":"Week 48: Social Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.96","spread":"7.987"},{"groupId":"OG001","value":"-0.68","spread":"6.851"}]}]},{"title":"Week 48: Emotional Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"3.095"},{"groupId":"OG001","value":"0.41","spread":"4.166"}]}]},{"title":"Week 48: Functional Well-Being (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"3.894"},{"groupId":"OG001","value":"0.55","spread":"5.448"}]}]},{"title":"Week 48: FACT-L Subscale Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"4.445"},{"groupId":"OG001","value":"0.82","spread":"5.967"}]}]},{"title":"Week 48: Lung Cancer Subscale Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"3.100"},{"groupId":"OG001","value":"0.34","spread":"5.150"}]}]},{"title":"Week 48: Total FACT-G Score (n=13,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.57","spread":"12.233"},{"groupId":"OG001","value":"1.64","spread":"14.463"}]}]},{"title":"Week 48: Trial Outcome Index (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.79","spread":"7.570"},{"groupId":"OG001","value":"2.26","spread":"13.247"}]}]},{"title":"Week 48: Total FACT-L Score (n=12,29)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.60","spread":"11.354"},{"groupId":"OG001","value":"2.46","spread":"18.177"}]}]},{"title":"Week 60: Physical Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"5.383"},{"groupId":"OG001","value":"1.82","spread":"6.307"}]}]},{"title":"Week 60: Social Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"7.368"},{"groupId":"OG001","value":"0.06","spread":"9.116"}]}]},{"title":"Week 60: Emotional Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"2.789"},{"groupId":"OG001","value":"0.28","spread":"4.478"}]}]},{"title":"Week 60: Functional Well-Being (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"3.877"},{"groupId":"OG001","value":"-0.53","spread":"7.434"}]}]},{"title":"Week 60: FACT-L Subscale Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"5.882"},{"groupId":"OG001","value":"0.43","spread":"6.275"}]}]},{"title":"Week 60: Lung Cancer Subscale Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"4.438"},{"groupId":"OG001","value":"0.47","spread":"5.535"}]}]},{"title":"Week 60: Total FACT-G Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"12.270"},{"groupId":"OG001","value":"1.64","spread":"17.542"}]}]},{"title":"Week 60: Trial Outcome Index (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"11.044"},{"groupId":"OG001","value":"1.76","spread":"14.316"}]}]},{"title":"Week 60: Total FACT-L Score (n=9,17)","categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"15.700"},{"groupId":"OG001","value":"2.07","spread":"22.086"}]}]},{"title":"Week 72: Physical Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"6.318"},{"groupId":"OG001","value":"2.63","spread":"7.130"}]}]},{"title":"Week 72: Social Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"6.723"},{"groupId":"OG001","value":"0.30","spread":"3.733"}]}]},{"title":"Week 72: Emotional Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"3.619"},{"groupId":"OG001","value":"-0.13","spread":"4.853"}]}]},{"title":"Week 72: Functional Well-Being (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"5.354"},{"groupId":"OG001","value":"-1.13","spread":"5.384"}]}]},{"title":"Week 72: FACT-L Subscale Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"7.396"},{"groupId":"OG001","value":"1.03","spread":"4.818"}]}]},{"title":"Week 72: Lung Cancer Subscale Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":"5.193"},{"groupId":"OG001","value":"1.78","spread":"4.141"}]}]},{"title":"Week 72: Total FACT-G Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"11.929"},{"groupId":"OG001","value":"1.67","spread":"14.651"}]}]},{"title":"Week 72: Trial Outcome Index (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"13.097"},{"groupId":"OG001","value":"3.28","spread":"13.738"}]}]},{"title":"Week 72: Total FACT-L Score (n=6,8)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.03","spread":"16.140"},{"groupId":"OG001","value":"2.70","spread":"17.579"}]}]},{"title":"Week 84: Physical Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Social Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Emotional Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Functional Well-Being (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: FACT-L Subscale Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Lung Cancer Subscale Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Total FACT-G Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.67","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Trial Outcome Index (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Week 84: Total FACT-L Score (n=1,0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"NA","comment":"SD not calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Zero participants were analyzed"}]}]},{"title":"Off Trtmt: Physical Well-Being (n=264,214)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"4.750"},{"groupId":"OG001","value":"-2.19","spread":"5.506"}]}]},{"title":"Off Trtmt: Social Well-Being (n=263,216)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"4.973"},{"groupId":"OG001","value":"0.09","spread":"4.824"}]}]},{"title":"Off Trtmt: Emotional Well-Being (n=264,216)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"4.225"},{"groupId":"OG001","value":"-1.56","spread":"4.745"}]}]},{"title":"Off Trtmt: Functional Well-Being (n=264,216)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"5.170"},{"groupId":"OG001","value":"-1.98","spread":"5.355"}]}]},{"title":"Off Trtmt: FACT-L Subscale Score (n=263,212)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"4.458"},{"groupId":"OG001","value":"-1.32","spread":"4.708"}]}]},{"title":"Off Trtmt: Lung Cancer Subscale Score (n=263,212)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"3.882"},{"groupId":"OG001","value":"-1.78","spread":"4.199"}]}]},{"title":"Off Trtmt: Total FACT-G Score (n=260,213)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.91","spread":"12.576"},{"groupId":"OG001","value":"-5.71","spread":"13.588"}]}]},{"title":"Off Trtmt: Trial Outcome Index (n=261,210)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.03","spread":"10.658"},{"groupId":"OG001","value":"-6.05","spread":"11.785"}]}]},{"title":"Off Trtmt: Total FACT-L Score (n=258,209)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.26","spread":"15.146"},{"groupId":"OG001","value":"-7.10","spread":"16.194"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events (AEs) were recorded from Day 1 (after randomization) through the end of study, up to 27 months. Serious adverse events (SAEs) were recorded from Day 1 (after randomization) through the second data cut-off, up to 71 months.","description":"All participants who received at least 1 dose of investigational treatment and had at least 1 safety follow-up, whether prematurely withdrawn or not, were included in the safety analysis.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive a placebo, PO as tablets, daily, from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months.","seriousNumAffected":34,"seriousNumAtRisk":445,"otherNumAffected":152,"otherNumAtRisk":445},{"id":"EG001","title":"Erlotinib, 150 mg/Day","description":"Participants completed 4 cycles (3 or 4 week cycles) of a standard platinum based non-investigational chemotherapy according to local practice and in concordance with the local labeling instructions (chemotherapy run-in period). Participants who completed all 4 cycles of chemotherapy run-in without PD according to RECIST were randomized to receive erlotinib, 150 mg/day, PO as tablets from randomization until PD, death, unacceptable toxicity, or end of study, up to 27 months.","seriousNumAffected":49,"seriousNumAtRisk":433,"otherNumAffected":283,"otherNumAtRisk":433}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":445},{"groupId":"EG001","numAffected":7,"numAtRisk":433}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Catheter sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":2,"numAtRisk":433}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Nocardiosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Staphylococcal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":2,"numAtRisk":433}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":2,"numAtRisk":433}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Pleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":4,"numAtRisk":433}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Gastric perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Urogenital haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":2,"numAtRisk":433}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Drowning","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":2,"numAtRisk":433}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Left ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Aortic aneurysm","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Arteritis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":445},{"groupId":"EG001","numAffected":0,"numAtRisk":433}]},{"term":"Iliac artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":1,"numAtRisk":433}]}],"otherEvents":[{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":445},{"groupId":"EG001","numAffected":211,"numAtRisk":433}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":445},{"groupId":"EG001","numAffected":32,"numAtRisk":433}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":445},{"groupId":"EG001","numAffected":27,"numAtRisk":433}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":445},{"groupId":"EG001","numAffected":87,"numAtRisk":433}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":445},{"groupId":"EG001","numAffected":33,"numAtRisk":433}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":445},{"groupId":"EG001","numAffected":36,"numAtRisk":433}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":445},{"groupId":"EG001","numAffected":33,"numAtRisk":433}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":445},{"groupId":"EG001","numAffected":22,"numAtRisk":433}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":445},{"groupId":"EG001","numAffected":39,"numAtRisk":433}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":445},{"groupId":"EG001","numAffected":14,"numAtRisk":433}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":445},{"groupId":"EG001","numAffected":39,"numAtRisk":433}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffman-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}